GlassScriptPhysician profile
Alexander Q Ereso
NPI 1144480492
$12,523.63
in general payments reported to CMS, 2019-2025
9 companies · $3,413 in 2025
The $3,413 reported for 2025 was more than what 89% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,333 · 2020: $409 · 2021: $2,266 · 2022: $2,075 · 2023: $1,763 · 2024: $264 · 2025: $3,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,438 · Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,437.65 |
| Food and Beverage | $1,002.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,620.02 | 2019-2023 | |
| Abbvie INC. | $4,359.34 | 2023-2025 | |
| Merz North America, INC. | $439.46 | 2021-2025 | Xeomin |
| Mentor Worldwide LLC | $361.37 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Sientra, INC. | $313.09 | 2019-2022 | |
| Galderma Laboratories, L.P. | $235.10 | 2019-2020 | |
| Revance Therapeutics, INC. | $147.08 | 2025 | Daxxify |
| Boston Scientific Corporation | $26.37 | 2020 | |
| Heron Therapeutics, INC. | $21.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Ereso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.